Nektar Therapeutics Shares Soar 44% on Positive AD Data, Hit $55 Intraday
Nektar shares surged 44% after positive 36-week maintenance data from its REZOLVE-AD trial showed 71% (monthly) and 83% (quarterly) EASI-75 maintenance rates and up to a fivefold EASI-100 increase at week 52. Stock now trades 43% above its 20-day SMA, hit an intraday high of $55.43 and has climbed over 400% in the past year.
1. Positive Phase 2b REZOLVE-AD Data
Nektar reported that in the 36-week blinded maintenance period of its 52-week REZOLVE-AD Phase 2b study of rezpegaldesleukin in moderate-to-severe atopic dermatitis, 71% (24 µg/kg monthly) and 83% (quarterly) of patients maintained EASI-75 response rates, while 85% and 63% maintained vIGA-AD 0/1, with up to a fivefold increase in EASI-100 at week 52.
2. Stock Momentum and Technicals
Following the data release, shares jumped 44%, trading as high as $55.43, moving 43% above its 20-day simple moving average and 18.1% above its 50-day SMA, with a 12-month gain exceeding 400%, supported by a neutral RSI and a bullish MACD indicating continued upside potential.
3. Phase 3 Outlook
The durability of these maintenance responses paves the way for a pivotal Phase 3 program evaluating both monthly and quarterly maintenance dosing schedules, with investors focused on upcoming trial initiation, enrollment timelines and potential regulatory submission milestones.